Data from International Journal of Neuroscience - Curated by Marshall Pearce - Date available 27 November 2017

Availability

Pay for access, or by subscription

Article type

Review

Original date published

27 November 2017

Original format

Epub ahead of print

Introduction: Adjunctive lacosamide treatment might be promising to treat seizures. However, the results remained controversial. We conducted a systematic review and meta-analysis to compare the efficacy and safety of adjunctive lacosamide versus placebo in patients with seizures.

Methods: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of adjunctive lacosamide versus placebo on seizures were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcomes were 50% responder rate and seizure freedom. Meta-analysis was performed using the fixed-effect or random-effect model when appropriate.

Results: Four RCTs involving 1199 patients were included in the meta-analysis. Overall, compared with placebo treatment, adjunctive lacosamide treatment was associated with a significantly increased 50% responder rate (RR = 1.89; 95% CI = 1.51 to 2.36; P<0.00001) and seizure freedom (RR = 4.97; 95% CI = 1.78 to 13.91; P = 0.002), but improved dizziness (RR = 3.97; 95% CI = 2.91 to 5.42; P<0.00001), nausea (RR = 2.85; 95% CI = 1.75 to 4.66; P<0.0001), vomiting (RR = 4.11; 95% CI = 2.23 to 7.57; P<0.00001), diplopia (RR = 6.85; 95% CI = 3.36 to 13.94; P<0.00001), treatment-emergent adverse events (RR = 2.29; 95% CI = 1.93 to 2.71; P<0.00001), and serious adverse events (RR = 2.52; 95% CI = 1.33 to 4.78; P = 0.005).

Conclusions: Compared to placebo treatment, adjunctive lacosamide treatment resulted in a significantly improved 50% responder rate and seizure freedom, but with increased dizziness, nausea, vomiting, diplopia, treatment-emergent adverse events, and serious adverse events.

Data sources

Read abstract on library site Access full article

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Related Content